Patients with advanced hepatocellular carcinoma (HCC) receiving atezolizumab-bevacizumab treatment were more likely to experience variceal bleeding if they had a low platelet count, main portal ...

Exelixis (EXEL) announced results from an expansion cohort of the phase 1b/2 STELLAR-001 trial evaluating zanzalintinib alone or in combination with atezolizumab in patients with previously ...

Relevance section written by JCO Associate Editor Gary K. Schwartz, MD, FASCO. The phase Ib COSMIC-021 study evaluated cabozantinib plus atezolizumab in patients with advanced solid tumors. Presented ...

Patients with HCC at high risk of recurrence after resection or local ablation were randomly assigned to receive either atezolizumab plus bevacizumab or active surveillance in the IMbrave 050 study.